SEC Form 4 · accession 0001127602-16-050557
LEXICON PHARMACEUTICALS, INC. · LXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alan S Nies
Director
Period of report
Apr 29, 2016
Accepted (ET)
May 2, 2016 · 5:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001062822
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 29, 2016 | A | 1,432 | $0.00 | A | 9,771 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.96 | Apr 29, 2016 | A | 2,857 | A | — | Apr 29, 2026 | Common Stock | 2,857 | 2,857 | D |
| Stock Option (Right to Buy)F2 | $26.39 | holding | — | — | — | — | Apr 26, 2017 | Common Stock | 1,428 | 1,428 | D |
| Stock Option (Right to Buy)F2 | $15.40 | holding | — | — | — | — | Apr 24, 2018 | Common Stock | 1,428 | 1,428 | D |
| Stock Option (Right to Buy)F2 | $6.93 | holding | — | — | — | — | Apr 24, 2019 | Common Stock | 1,428 | 1,428 | D |
| Stock Option (Right to Buy)F1 | $13.86 | holding | — | — | — | — | May 10, 2023 | Common Stock | 2,857 | 2,857 | D |
| Stock Option (Right to Buy)F1 | $10.78 | holding | — | — | — | — | Apr 30, 2020 | Common Stock | 1,428 | 1,428 | D |
| Stock Option (Right to Buy)F1 | $11.83 | holding | — | — | — | — | Apr 29, 2021 | Common Stock | 1,428 | 1,428 | D |
| Stock Option (Right to Buy)F1 | $11.90 | holding | — | — | — | — | Apr 27, 2022 | Common Stock | 2,857 | 2,857 | D |
| Stock Option (Right to Buy)F1 | $10.92 | holding | — | — | — | — | Apr 25, 2024 | Common Stock | 2,857 | 2,857 | D |
| Stock Option (Right to Buy)F1 | $7.49 | holding | — | — | — | — | Apr 24, 2025 | Common Stock | 2,857 | 2,857 | D |
Explanation of responses
- F1Option vests with respect to 1/12th of the shares subject to the option for each month of service following the date of grant.
- F2Option vests with respect to 1/12th of the shares subject to the option for each month of service following the date of grant.